Zobrazeno 1 - 10
of 1 232
pro vyhledávání: '"Thomas Mueggler"'
Autor:
Henrik Zetterberg, Kaj Blennow, José Luis Molinuevo, Andreea Radoi, Carolina Minguillón, Karine Fauria, Carme Deulofeu, Marc Suárez-Calvet, Oriol Grau-Rivera, Alex Iranzo, Iva Knezevic, Núria Tort-Colet, Laura Stankeviciute, Laura Hernández, Sherezade Fuentes-Julián, Israel Turull, David Fusté, Gonzalo Sánchez-Benavides, Eider M Arenaza-Urquijo, Sebastian C Holst, Pilar Garcés, Thomas Mueggler, Aurora Arqueros, Juan Domingo Gispert
Publikováno v:
BMJ Open, Vol 12, Iss 12 (2022)
Introduction The growing worldwide prevalence of Alzheimer’s disease (AD) and the lack of effective treatments pose a dire medical challenge. Sleep disruption is also prevalent in the ageing population and is increasingly recognised as a risk facto
Externí odkaz:
https://doaj.org/article/c793807a0174443da3ac6afb35420871
Publikováno v:
Cell Reports, Vol 20, Iss 8, Pp 1867-1880 (2017)
The NMDA receptor (NMDAR) antagonist ketamine elicits a long-lasting antidepressant response in patients with treatment-resistant depression. Understanding how antagonism of NMDARs alters synapse and circuit function is pivotal to developing circuit-
Externí odkaz:
https://doaj.org/article/5f4a90a5441040d284ff9eac8da96f05
Publikováno v:
Neurobiology of Disease, Vol 40, Iss 1, Pp 284-292 (2010)
Deposition of β-amyloid along cerebral vessels is found in most patients suffering from Alzheimer's disease. The effects of cerebral amyloid angiopathy (CAA) on the function of cerebral blood vessels were analyzed applying cerebral blood volume (CBV
Externí odkaz:
https://doaj.org/article/8d07fe78f8b1491590326844da6b7ca2
Autor:
Dany V D'Souza, Elisabeth Jonckers, Andreas Bruns, Basil Künnecke, Markus von Kienlin, Annemie Van der Linden, Thomas Mueggler, Marleen Verhoye
Publikováno v:
PLoS ONE, Vol 9, Iss 9, p e106156 (2014)
Translation of resting-state functional connectivity (FC) magnetic resonance imaging (rs-fMRI) applications from human to rodents has experienced growing interest, and bears a great potential in pre-clinical imaging as it enables assessing non-invasi
Externí odkaz:
https://doaj.org/article/a2a3e1ea172c4f3a908ce0c7e6a21089
Autor:
Karine Fauria, Carolina Minguillon, Iva Knezevic, Núria Tort-Colet, Laura Stankeviciute, Laura Hernández, Andreea Rădoi, Carme Deulofeu, Sherezade Fuentes-Julián, Israel Turull, David Fusté, Gonzalo Sánchez-Benavides, Eider M Arenaza-Urquijo, Marc Suárez-Calvet, Sebastian C Holst, Pilar Garcés, Thomas Mueggler, Henrik Zetterberg, Kaj Blennow, Aurora Arqueros, Álex Iranzo, Juan Domingo Gispert, José Luis Molinuevo, Oriol Grau-Rivera
Publikováno v:
BMJ open. 12(12)
Introduction: the growing worldwide prevalence of Alzheimer's disease (AD) and the lack of effective treatments pose a dire medical challenge. Sleep disruption is also prevalent in the ageing population and is increasingly recognised as a risk factor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::738a649d940358767ab8c993bcd87726
https://pubmed.ncbi.nlm.nih.gov/36585141
https://pubmed.ncbi.nlm.nih.gov/36585141
Autor:
Schnider Patrick, Erwin Goetschi, Neil Parrott, Hasane Ratni, Markus von Kienlin, Basil Künnecke, Celine Risterucci, Cosimo Dolente, Mark Rogers-Evans, Roland Jakob-Roetne, Christophe Grundschober, Andreas Bruns, Caterina Bissantz, Emmanuel Pinard, Wolfgang Muster, Thomas Mueggler
Publikováno v:
Journal of medicinal chemistry. 63(4)
We recently reported the discovery of a potent, selective, and brain-penetrant V1a receptor antagonist, which was not suitable for full development. Nevertheless, this compound was found to improve surrogates of social behavior in adults with autism
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21b81a9362ac94dbb48af9cbb342a3c3
https://pubmed.ncbi.nlm.nih.gov/31951127
https://pubmed.ncbi.nlm.nih.gov/31951127
Autor:
Nina Jährling, Angelos Skodras, Mathias Jucker, Bettina M. Wegenast-Braun, Stephan A. Kaeser, Daniel Eicke, Hans-Ulrich Dodt, Ulrike Obermueller, David P. Wolfer, Derya R. Shimshek, Thomas Mueggler, Matthias Staufenbiel, Sarah K. Fritschi, Juliane Schelle, Lisa M. Häsler, Natalie Beschorner, Ulf Neumann
Publikováno v:
Annals of neurology 86(4), 561-571 (2019). doi:10.1002/ana.25562
Objective Clinical trials targeting β-amyloid peptides (Aβ) for Alzheimer disease (AD) failed for arguable reasons that include selecting the wrong stages of AD pathophysiology or Aβ being the wrong target. Targeting Aβ to prevent cerebral amyloi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b84045137144faa99c754e085815120
https://www.zora.uzh.ch/id/eprint/173281/
https://www.zora.uzh.ch/id/eprint/173281/
Depression is a pervasive and debilitating neuropsychiatric disorder. A single, low dose of the NMDA receptor (NMDAR) antagonist ketamine elicits a long-lasting antidepressant response in patients with treatment-resistant major depressive disorder. D
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b05b0df00a77941cb5b2ddddc545d953
https://doi.org/10.1101/106419
https://doi.org/10.1101/106419
Publikováno v:
Cell Reports, Vol 20, Iss 8, Pp 1867-1880 (2017)
Summary The NMDA receptor (NMDAR) antagonist ketamine elicits a long-lasting antidepressant response in patients with treatment-resistant depression. Understanding how antagonism of NMDARs alters synapse and circuit function is pivotal to developing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cb896ce03a8785a78ca64c4d1a84464
https://pubmed.ncbi.nlm.nih.gov/28834750
https://pubmed.ncbi.nlm.nih.gov/28834750
Autor:
Eva Mracsko, Nadine Pettkus, Benedikt Wefers, Regina Feederle, Marc Suárez-Calvet, Christian Haass, Thomas Mueggler, Maximilian Deußing, Matthias Brendel, Carola Focke, Peter Bartenstein, Irene Knuesel, Samira Parhizkar, Wolfgang Wurst, Thomas Arzberger, Xianyuan Xiang, Linda Groeneweg, Fargol Mazaheri, Axel Rominger, Gernot Kleinberger
Publikováno v:
The EMBO journal 36(13), 1837-1853 (2017). doi:10.15252/embj.201796516
EMBO J., DOI: 10.15252/embj.201796516 (2017)
EMBO J., DOI: 10.15252/embj.201796516 (2017)
Genetic variants in the triggering receptor expressed on myeloid cells 2 (TREM2) increase the risk for several neurodegenerative diseases including Alzheimer9s disease and frontotemporal dementia (FTD). Homozygous TREM2 missense mutations, such as p.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddff753a1eb7c1cc155936e3ac53e1fd
https://pub.dzne.de/record/139349
https://pub.dzne.de/record/139349